• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300725.SZ
Share

PharmaBlock Sciences Stocks

CN¥ 32.05Last Updated 12.06.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

CN¥ 950.11M

CN¥ 32.05
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PharmaBlock Sciences (Nanjing), Inc. delivers a comprehensive suite of chemical products and specialized services, supporting the pharmaceutical industry across the full spectrum of its operations – from initial research and development phases to large-scale commercial production. The company's primary offerings encompass: A vast inventory of chemical building blocks, available for supply at every stage of drug creation, from early discovery through to advanced development and commercial manufacturing. The creation of diverse chemical libraries, derived from their building blocks, specifically designed to accelerate drug discovery processes. Contract development and manufacturing (CDMO) services for essential pharmaceutical components, including raw starting materials (RSMs), chemical intermediates, active pharmaceutical ingredients (APIs), and finished drug products, catering to both clinical development programs and market demands. Established in 2006, PharmaBlock Sciences maintains its corporate headquarters in Nanjing, People's Republic of China.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair value on EV/

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 300725.SZ is 47 and suggests 50% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

13.06.2026 01:04

SpaceX shares slowed before closing in first trading since record IPO

13.06.2026 00:44

Retail investors bought $15 billion worth of SpaceX stock. Demand was at least 6 times that amount

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026